How does LSTA's EPS outlook for Q1 2025 compare to past trends?

Lisata Therapeutics (LSTA) has historically experienced significant fluctuations in its EPS, with a notable decline in recent years. The EPS for Q1 2025 is not currently available, but the trend leading up to this point suggests a potential for continued volatility. 1. **Comparison to Past Trends**: LSTA's EPS has been negative for the past few quarters, with a significant drop to -$2.58 in 2023Q4 and further to -$2.4 in 2024Q4. This trend of decreasing EPS suggests that the company may be facing challenges or managing its finances differently, which could impact its outlook for Q1 2025. 2. **Potential for Volatility**: The absence of positive EPS figures in the recent past indicates that LSTA's financial performance is currently under pressure. The EPS for Q1 2025 is likely to reflect this trend, potentially remaining negative or showing only slight improvements due to the lack of positive trends in the recent history. 3. **Consideration of External Factors**: It's important to consider external factors that could influence LSTA's financial performance, such as market conditions, regulatory changes, and company-specific developments. These factors can significantly impact a company's EPS and should be taken into account when assessing the outlook for Q1 2025. In conclusion, LSTA's EPS outlook for Q1 2025 is expected to continue the trend of negative EPS due to the company's recent performance and the absence of positive indicators. The potential for volatility remains high, and external factors will likely play a significant role in shaping the company's financial results for the period.